Employees: 3,401
Size Nephrocare Health Services (NEPHROPLUS.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $702M, the 723rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹653.00 on 18 Nov 2026.
Performance Over six months the shares gained 0.5%, against -8.6% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 32.9% over the last twelve months (peer median +5.2%); the operating margin is 13.1% (peer median 7.5%).
Valuation It trades at 48.8× forward earnings against a peer median of 17.4× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (12.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹11.1B | ₹9.97B | ₹7.50B | ₹5.57B | ₹4.37B |
| Revenue growth | — | +33% | +35% | +27% | — |
| Gross profit | ₹3.65B | ₹2.88B | ₹1.73B | ₹1.06B | ₹537M |
| EBITDA | ₹2.46B | ₹2.27B | ₹1.63B | ₹945M | ₹486M |
| Net income | ₹1.28B | ₹768M | ₹671M | ₹351M | -₹118M |
| Free cash flow | n/a | ₹1.03B | ₹298M | -₹141M | -₹699M |
| Capital expenditure | n/a | ₹1.19B | ₹1.01B | ₹800M | ₹737M |
| Total debt | ₹1.49B | ₹797M | ₹2.58B | ₹2.68B | ₹2.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEPHROPLUS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.8% | -1.8% | 5th highest of 21 |
| 6-month return | +0.5% | -8.6% | 9th highest of 21 |
| Distance from 52-week high | -16.4% | -30.8% | 5th highest of 21 |
| Revenue growth (TTM) | +32.9% | +5.2% | 3rd highest of 21 |
| Operating margin | 13.1% | 7.5% | 5th highest of 21 |
| Forward P/E | 48.8× | 17.4× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 36.6% | 6.8% | most demanding of 17 |
| Growth delivered (Del g) | +31.6% | +11.5% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | +5.0 pp | -9.1 pp | 4th most demanding of 17 |
| ROIC minus cost of capital | -0.3 pp | -0.1 pp | 10th lowest of 20 |
| EV / EBITDA | 25.5× | 7.7× | 2nd most expensive of 15 |
| Net debt / EBITDA | -1.2× | 1.6× | 4th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 12.3× | -4.7% | +12.2% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |